Tenpoint Therapeutics has launched a telehealth prescribing program for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, providing adults with presbyopia an online option to determine their eligibility for a prescription treatment for presbyopia.

The program connects eligible adults with an ophthalmologist or optometrist for a virtual evaluation to determine whether Yuvezzi is appropriate. Patients can access the service through orderYuvezzi.com or by calling 800-204-3511.

According to Tenpoint, the initiative is intended to complement rather than replace routine in-person eye care. Participants will be encouraged to establish and maintain relationships with local eye care professionals for comprehensive examinations and ongoing eye health management.

To support that effort, the company has also launched Yuvezzidoctor.com, an online resource designed to help patients locate eye care professionals in their communities.

“Many adults experiencing blurry close-up vision – especially those who don’t have an ophthalmologist or optometrist – may not realize that new prescription eye drops like Yuvezzi are an option to help reduce the constant need for reading glasses,” said Carol Kearney, chief commercial officer of Tenpoint Therapeutics.

Ms. Kearney added that the telehealth initiative is intended to expand access to treatment evaluations while reinforcing the importance of comprehensive eye care and supporting local practices.

Previously known as Brimochol PF, Yuvezzi was approved by the FDA in January 2026.